Abstract
Background & objectives Preoperative anxiety can be reduced pharmacologically. Midazolam is a benzodiazepine potent sedative, hypnotic, anaesthetic agent with strong anticonvulsant properties but does not have analgesic properties. The administration of intranasal lidocaine prior to the use of intranasal midazolam has been reported to be beneficial in reducing the burning sensation from intranasal midazolam. Dexmedetomidine, the newest sedative, is a highly selective α2 adrenergic agonist. Materials and methods Sixty children, aged between 3–12 years. The children were divided into two groups of 30 each. Thirty minutes before induction, Group-D (n=30) received intranasal Dexmedetomidine and Group M+L received intranasal midazolam preceeded by single puff on intranasal lidocaine spray 1% in each nostril. Results Children who were premedicated with intranasal dexmedetomidine had lower sedation (MOAA/S Scale) scores, and easier child-parent separation than children who received intranasal midazolam. In addition to lower BIS measurements at the OR, after face mask application and after IV cannulation. Conclusion Intranasal Dexmedetomidine can be used effectively and safely as a preanaesthetic medication in children undergoing repair of non-complex congenital cardiac defects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Research and Opinion in Anesthesia and Intensive Care
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
